Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL...
Main Authors: | Meri A. Shervashidze, Timur T. Valiev, Natalia A. Batmanova, Nikolai N. Tupitsyn, Irina N. Serebryakova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2020-05-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/34006/21716 |
Similar Items
-
Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease
by: M. A. Shervashidze, et al.
Published: (2020-10-01) -
Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002
by: T. T. Valiev, et al.
Published: (2022-07-01) -
Leukemia-associated immunophenotype of tumor cells in childhood B-precursors acute lymphoblastic leukemia
by: L. V. Movchan
Published: (2014-07-01) -
Leukemia-associated immunophenotype of tumor cells in childhood B-precursors acute lymphoblastic leukemia
by: L. V. Movchan
Published: (2014-07-01) -
The role of minimal residual disease in therapy of pediatric acute lymphoblastic leukemia: a prospective cohort study
by: Yulia S. Korkina, et al.
Published: (2023-05-01)